IMMUNE-MODULATING EFFECTS OF COLD-FXTRADEMARK SHOWN IN CLINICAL TRIAL:
CV Technologies Inc. has provided preliminary results suggesting that Cold-FX affects the human immune system by targeting the adaptive pathway, which is the immunity developed throughout life.
CV Technologies Inc. has provided preliminary results suggesting that Cold-FX affects the human immune system by targeting the adaptive pathway, which is the immunity developed throughout life.
This result was obtained through a randomized, double-blind, placebo-controlled trial of the company's lead product and Canada's No. 1 selling cold and flu remedy, Cold-FX, demonstrating its immune-modulating effects in front-line health care workers at New Jersey's prestigious Hackensack University Medical Center (HUMC).
The study was led by HUMC infectious diseases researcher Dr. Steven Sperber and extended previously published clinical research showing that regular intake of Cold-FX over a single cold season enhanced natural killer (NK) and T-helper cells, which are part of the body's immune defence system.
The study was led by HUMC infectious diseases researcher Dr. Steven Sperber and extended previously published clinical research showing that regular intake of Cold-FX over a single cold season enhanced natural killer (NK) and T-helper cells, which are part of the body's immune defence system.
Study participants were 50 healthy staff members from HUMC who were given either Cold-FX or a placebo. They consumed 1,800, 1,200 and 600 milligrams per day, respectively, on three consecutive days. Before and after each of the three days, blood samples were assessed for immune factors that are highly sensitive and therefore render a 50-person sample size statistically significant.
The results indicate that Cold-FX affects adaptive immunity, which is acquired through exposure to viruses and other infectious agents over time. Specifically, statistically significant results showed that T-helper lymphocytes -- which contribute to adaptive immunity -- rose after three days in the Cold-FX group but not in the placebo group.
Also of interest in the study was a statistically significant decrease in reported adverse events in the Cold-FX group compared with the placebo group. The implications of this are encouraging and consistent with some earlier scientific findings.
